About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, March 16th, 2015

The QualityStocks
Daily Stock List


Sunshine Biopharma, Inc. (SBFM)

Greenbackers, Jet-Life Penny Stocks, Shiznit Stocks, Fast Money Alerts, MassiveStockProfits, Stock Shock and Awe, Penny Stock General, PennyStocks24, Whisper from Wall Street, and Otcstockexchange reported earlier on Sunshine Biopharma, Inc. (SBFM), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Sunshine Biopharma, Inc. is a pharmaceutical company concentrating on the research, development, and commercialization of drugs for the treatment of different forms of cancer. The Company’s commitment is to developing novel therapies for the treatment of different forms of aggressive cancer types. Sunshine Biopharma has its Canadian wholly-owned subsidiary: Sunshine Biopharma Canada, Inc. This subsidiary conducts pharmaceutical business in Canada and elsewhere worldwide.

Sunshine Biopharma’s first drug candidate, Adva-27a, is a small molecule that has proven effective against diverse kinds of multidrug resistant cancer cell lines. These include breast cancer (MCF-7/MDR), small-cell lung cancer (H69AR), uterine carcinoma (MES-SA/Dx5) and pancreatic cancer (Panc-1).

Sunshine Biopharma’s Adva-27a is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for different forms of cancer.  Adva-27a is now in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.

The Company entered into a collaboration agreement in January of 2011 with Binghamton University (State University of New York at Binghamton, New York). This agreement is to conduct certain research and development activities intended at advancing Sunshine Biopharma’s lead compound, Adva-27a, through different stages of preclinical development.

Sunshine Biopharma entered into a Clinical Trials Agreement in June of 2011 with The Jewish General Hospital, one of McGill University’s Hospital Centers, to conduct certain R&D activities and advance its Adva-27a through the various stages of preclinical studies and Phase I clinical trials on multidrug resistant breast cancer patients. The Company is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University's Jewish General Hospital in Montreal.

Sunshine Biopharma has an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a. Lonza has expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients. Manufacturing will be at Lonza's Nansha, China facility. The remaining key steps will take place in Lonza's high containment cytotoxic facility in Visp, Switzerland.

Last month, Sunshine Biopharma announced the appointment of Dr. Abderrazzak Merzouki to the Board of Directors and to the office of Chief Operating Officer (COO) to replace Mr. Michele Di Turi. Mr. Di Turi resigned as a Director and COO of the Company to pursue other interests. Dr. Merzouki is an accomplished scientist with more than 20 years of experience in virology and immunology.

Sunshine Biopharma, Inc. (SBFM), closed Monday's trading session at $0.0157, up 15.44%, on 2,366,400 volume with 38 trades. The average volume for the last 60 days is 185,831 and the stock's 52-week low/high is $0.013/$0.27.

Quantum Materials Corp. (QTMM)

TopPennyStockMovers reported recently on Quantum Materials Corp. (QTMM), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

Quantum Materials Corp. manufactures Tetrapod Quantum Dots for use in medical, display, solar energy and lighting applications through its patent-pending volume production process. Tetrapod Quantum Dot semiconductors allow a new level of engineered performance for consumer and industrial products. Quantum dots fall into the category of nanocrystals. This additionally includes quantum rods and nanowires. Quantum Dots measure near one billionth of an inch. They are a non-traditional type of semiconductor. They can be used as an enabling material across many industries. They have first-rate versatility and are flexible in form.

The San Marcos, Texas-based Company has its its wholly-owned subsidiary, Solterra Renewable Technologies, Inc. Solterra concentrates on manufacturing solar cells for retail electricity markets in North America, Europe, the Middle East, and Asia. Solterra Renewable Technologies develops sustainable solar technology through replacing silicon wafer-based solar cells with high-production, low-cost, efficient and flexible thin-film quantum dot solar cells. Solterra’s intention is to market a thin-film photovoltaic cell incorporating the Company’s proprietary quantum dot semiconductors.   

Solterra will utilize Quantum Materials’ exclusive license from University of Arizona Regents for Dr. Ghassan Jabbour’s patented printing technology in the production of its solar cells. Solterra’s objective is to become the first solar cell manufacturer that can offer a solar electricity solution that competes on a non-subsidized basis with the price of retail electricity in the above-mentioned key markets.

Quantum Materials announced in June 2014 securing 3D printing and additive manufacturing anti-counterfeiting quantum dot detection technology. This was developed at the Institute for Critical Technology and Applied Science and the Design, Research, and Education for Additive Manufacturing Systems (DREAMS) Laboratory at Virginia Tech. This technology embeds quantum dots within objects being 3D printed to produce a unique, physically uncloneable signature known only to the object's manufacturer.

Quantum Materials has signed an agreement with STAR Park, which will quadruple the Company’s Quantum Dot production space when the new state-of-the-art lab and offices are finished on or before June 2015. Moreover, Quantum Materials is recruiting to double its scientific staff effective this past January.

Recently, Quantum Materials announced it is increasing production capacity to 2,000 kilograms (2 metric tons) of quantum dots and nanoparticles annually in Q2 2015. It is able to take advantage of short development timelines to plan for increasing quantum dot production. The Company anticipates more production expansion during the remainder of this year.

Last month, Quantum Materials announced that it has started shipping Cadmium-free red and green quantum dots in evaluation and production quantities to select leading consumer electronics manufacturers. It has increased the uniformity and enhanced stability of its Cadmium-free nanomaterials due to bringing previously-reported automated capital equipment, facility, as well as personnel investments online.

Quantum Materials Corp. (QTMM), closed Monday's trading session at $0.162, up 4.52%, on 1,085,950 volume with 99 trades. The average volume for the last 60 days is 319,091 and the stock's 52-week low/high is $0.0539/$0.45.

Aethlon Medical, Inc. (AEMD)

PennyStocks24, Tip.us, SmallCapVoice, and SmallCap Network reported recently on Aethlon Medical, Inc. (AEMD), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Aethlon Medical, Inc.'s mission is to create novel medical devices, which address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Company’s Aethlon ADAPT™ System (Adaptive Dialysis-Like Affinity Platform Technology) is a revenue-stage technology platform. The ADAPT™ system provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. Aethlon Medical has its corporate headquarters in San Diego, California.

Aethlon Medical has its Exosome Sciences, Inc. (ESI). This is the Company’s majority-owned subsidiary established by Aethlon to pursue exosome-based strategies to diagnose and monitor cancer, infectious disease, and neurological disorders.

The Aethlon ADAPT™ System is a medical device platform. It joins single or multiple affinity drug agents with advanced plasma membrane technology. This is to create therapeutic filtration devices that selectively remove harmful particles from the entire circulatory system without the loss of essential blood components. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer.

Aethlon Medical’s Aethlon Hemopurifier® is a first-in-class medical device with broad spectrum capabilities against viral pathogens. These include the human immunodeficiency virus (HIV), hepatitis C virus (HCV), and numerous bioterror and pandemic threats.

The Company also has its ELLSA™ Exosome Assay. This is an enzyme-linked lectin-specific assay/ It has demonstrated the ability to identify and quantify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and all forms of cancer tested so far.

The Company’s pipeline also includes a medical device undergoing development under a five-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers (DARPA Sepsis Program). Aethlon also has its HER2osome™. It provides a therapeutic strategy to maximize the ability of the immune system and established drug therapies to combat HER2+ breast cancer.

In early January, Aethlon Medical said the U.S. Food and Drug Administration (FDA) approved the testing in Ebola patients of its bio-filtration device, which was used against the virus in a critically ill patient in Germany who later recovered. The device is being developed as a broad-spectrum countermeasure against pandemic threats. It filters viruses and toxins from the blood.

Last month, Aethlon Medical announced that the first patient enrolled in its FDA approved feasibility study completed their full Hemopurifier® treatment protocol without any device-related adverse events. The study protocol is being administered at DaVita Med Center Dialysis in Houston, Texas. It is enrolling ten chronic dialysis patients infected with Hepatitis C virus (HCV) to receive a six treatment protocol of Hemopurifier therapy.

Aethlon Medical, Inc. (AEMD), closed Monday's trading session at $0.235, up 15.76%, on 2,011,042 volume with 269 trades. The average volume for the last 60 days is 1,251,525 and the stock's 52-week low/high is $0.1025/$0.72.

MEDL Mobile Holdings, Inc. (MEDL)

PennyStockRumors.net and PricelessPennyStocks reported earlier on MEDL Mobile Holdings, Inc. (MEDL), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Fountain Valley, California-based MEDL Mobile Holdings, Inc. develops, acquires and publishes an increasing library of mobile applications (apps). These apps perform specific functions for the user on the Apple and Android platforms. The Company is establishing a business model in which it expects to generate multiple revenue streams. These streams include development fees, download and in-app purchases, advertising, sponsorship, and licensing of technology.

MEDL Mobile's Software Development Kit (SDK) consists of a growing collection of tools designed to help developers to better market and monetize mobile applications. The Company has joined forces with Specific Media to supply mobile video advertising for MEDL Mobile's previously launched social media platform, "Hang w/." The Hang w/ platform enables live real-time video to be broadcast from one phone to many.

Broadcasters earn a percentage of the advertising revenue generated based upon the number of followers who are "Hanging w/" them. Anyone with an iPhone or Android device can connect instantaneously to a huge base of fans through live-streaming video broadcasts.

The agreement gives Specific Media the exclusive rights to sell all unfilled advertising on the platform. MEDL Mobile Holdings retains the rights to collaborate directly with brands and advertising agencies to sell advertising and sponsorship for individual celebrities and for Hang w/ "channels" of content. MEDL is the largest shareholder of Hang With, Inc.

Last week, MEDL Mobile Holdings announced that Hang w/ is partnering with Alan Tudyk (Firefly, Frozen, Dodgeball: A True Underdog Story, 42, I, Robot) and Nathan Fillion (Firefly, Castle, Monsters University, Dr. Horrible's Sing-Along Blog) to provide exclusive behind the scenes footage from the set of their new Web Series, Con Man. Hang w/'s "Private Access" broadcast function permits a broadcaster to share live-streaming video only with a select group of people. The Hang w/ platform has attracted hundreds of actors, athletes, musicians, as well as brands.

MEDL Mobile Holdings, Inc. (MEDL), closed Monday's trading session at $0.1351, up 8.08%, on 520,960 volume with 56 trades. The average volume for the last 60 days is 66,738 and the stock's 52-week low/high is $0.095/$0.31.

Terra Tech Corp. (TRTC)

SmallCapVoice reported this month on Terra Tech Corp. (TRTC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Terra Tech Corp., by way of its wholly-owned subsidiary GrowOp Technology, specializes in controlled environment agricultural technologies. It integrates best-of-breed hydroponic equipment with proprietary software and hardware to provide sustainable solutions for indoor agriculture enterprises and home practitioners. The Company works closely with expert horticulturists, engineers, and plant scientists to develop and manufacture advanced proprietary products for the developing urban agricultural industry and individual hobbyists. Terra Tech has its headquarters in Irvine, California.
Terra Tech operates in two distinct markets. One is Commercial Agriculture. The other is Retail Agriculture. Concerning Commercial, the Company works with customers to help design, develop, as well as manufacture cultivation systems that maximize space and decrease energy costs. It offers rooftop/vertical hydroponic and aeroponic systems to custom designed greenhouse management systems.

Pertaining to Retail, Terra Tech, through GrowOp Technology, designs and manufactures an advanced and affordable line of horticulture equipment. GrowOp Technology operates out of its warehouse facility in Oakland, California.

Furthermore, Terra Tech centers on medical cannabis cultivation technology. The Company’s products comprise Commercial Hydroponic and Aeroponic Systems with 'ADS' Automated Dosing Systems; Digital Atmospheric Controllers: Lighting, Humidity, C02 and more, and Commercial Greenhouse Manufacturing.

Through its wholly-owned subsidiary Edible Garden, Terra Tech cultivates a premier brand of local and sustainably grown hydroponic produce. This produce sells through leading grocery stores throughout New Jersey, New York, Delaware, Maryland, Connecticut, and Pennsylvania. Edible Garden has a new line of organic living produce. It received organic certification, from Baystate Organic Certifiers, for their line of 4" potted herbs.

Terra Tech has its subsidiaries MediFarm, MediFarm I and MediFarm II. MediFarm, MediFarm I, and MediFarm II, have all received provisional certificates from the State of Nevada in each local jurisdiction where they applied for a Medical Marijuana Establishment license. Together, these subsidiaries were issued a total of four Dispensary provisional certificates, two Cultivation provisional certificates, as well as two Production provisional certificates spanning Northern and Southern Nevada.

Last week, Terra Tech updated shareholders on the launch and continued development of IVXX branded cannabis products. It recently announced a new brand of premier quality cannabis products called IVXX, which is a wholly-owned subsidiary of Terra Tech. The Company offers a selection of expertly crafted cannabis extracts in the form of waxes, shatters, and concentrates. IVXX products are now being carried at BLUM, a medical cannabis dispensary located in downtown Oakland. Terra Tech will be announcing more retail partners in the coming weeks. IVXX produces medical cannabis extracted products sold to permitted medical cannabis dispensaries across California.

Terra Tech Corp. (TRTC), closed Monday's trading session at $0.184, up 4.84%, on 801,375 volume with 177 trades. The average volume for the last 60 days is 1,257,281 and the stock's 52-week low/high is $0.17/$1.23.

Las Vegas Railway Express, Inc. (XTRN)

SmallCapVoice and TheStockWizrds.net reported on Las Vegas Railway Express, Inc. (XTRN), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.

Las Vegas Railway Express, Inc. does business as X Train Holdings Corp. The Company has developed a strong infrastructure of call center, travel agency, logistics planning management, food and beverage, and unique passenger rail cars for acquiring or affiliating privately owned passenger rail companies under the X Train Holdings umbrella. Las Vegas Railway Express is based in Las Vegas, Nevada and the Company lists on the OTCQB.

Las Vegas Railway Express entered into an agreement on April 23, 2014 with Santa Fe Southern Railway, located in Santa Fe, New Mexico, to manage the passenger services on the railroad. Currently, X Train provides its Club X service on the Santa Fe Southern Railway in Santa Fe. X Train Vacations is its travel agency that books passenger rail excursions for 40 passenger railroad companies across the U.S. and custom parties on its Club X Train cars.

Las Vegas Railway Express, dba X Train Holdings, owns outright a series of 16 bi-level passenger railcars and two leased cars acquired by way of an agreement with Mid America Leasing Company. These cars are planned for use in the deployment of cars on the Company’s future affiliated routes and acquired companies.

Las Vegas Railway Express elected Mr. Ronald L. Batory as a Director, effective August 6, 2014. Currently, Mr. Batory is Chief Executive Officer for Consolidated Rail Corporation (CONRAIL). He has more than 43 years of experience in the railroad industry.

This past November, Las Vegas Railway Express, known as the Vegas X Train, announced that its travel agency, X Train Vacations, increased its extensive product line of rail travel, attractions, as well as hotel vacation packages across the U.S.  X Train Vacations is becoming one of the foremost luxury online travel websites. The Company has its new user friendly website www.xtrainvacations.com. It now offers easy access to book special train destinations, see shows, and get easy hotel lodging and more.

Las Vegas Railway Express, Inc. (XTRN), closed Monday's trading session at $0.0009, up 28.57%, on 837,960 volume with 6 trades. The average volume for the last 60 days is 7,906,030 and the stock's 52-week low/high is $0.0006/$0.70.

Leo Motors, Inc. (LEOM)

Wallstreetlivechat and Bull Trends reported earlier on Leo Motors, Inc. (LEOM), and we also report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed Leo Motors, Inc. engages in the development, manufacture, and sale of Electric Vehicle (EV) Power Trains and components. The Company has developed many original EV power trains. It has also converted a number of models of existing internal combustion engine (ICE) vehicles into EVs. Leo Motors has developed a Zinc Air Fuel Cell Generator (ZAFCG) that will free EVs from range limits, with zero emission.

Leo Motors established a wholly-owned operating subsidiary in 2006 in Korea called Leo Motors, Co. Ltd. (Leozone). Through Leozone, the Company engages in the R&D of multiple products, prototypes, and conceptualizations founded on proprietary, patented, and patent-pending electric power generation, drive train, and storage technologies. Leozone operates via four unincorporated divisions. These are new product R&D, post R&D development including product testing; production; and sales.

Products include Zinc Air Fuel Battery (ZAFC), electric vehicles (EV), EV components that integrate electric batteries with electric motors such as EV Controllers that use a mini-computer to control torque drive, and E-Box - an electric energy storage system for solar and wind power generation devices.

The E-Box can be used as an energy supplying device in emergency situations or as an energy storage device for use by the military; municipal and industry; corporate; solar/wind power storage; electric coolers and heaters; yachts or small ships. The E-Box is offered in three power classes: 1kw, 3kw and 5kw.

The E-Box is environmentally friendly with high energy density due to the use of lithium-polymer batteries. The E-Box uses a multiple cell voltage balancing system via a battery management system (BMS). The Company has concentrated its marketing and sales efforts on the E-Box. It indicated that E-Boxes for 10kw and 550kw will undergo development in the future.

Leo Motors also has its subsidiary company, Leo Greentier Marines (LGM). LGM has filed two patents that will considerably improve efficiency in the refrigerated cargo transportation of fresh food. This is while significantly decreasing the carbon footprint of bulk refrigerated vehicles. The new patent-pending technologies represent major novel cooling system advances for cost-effective, safe, as well as efficient transport of fresh food.

Moreover, this past December, Leo Motors announced that it signed the Memorandum of Understanding (MOU) with Eco Holdings to establish a joint venture (JV) company in Japan. Eco Holdings is a foremost solar energy company in Japan. The JV will manufacture and market electric fishing boats and energy storage systems in Japan.

Leo Motors, Inc. (LEOM), closed Monday's trading session at $0.064, up 1.59%, on 205,488 volume with 12 trades. The average volume for the last 60 days is 78,441 and the stock's 52-week low/high is $0.0227/$0.18.


The QualityStocks
Company Corner


Save The World Air, Inc. (ZERO)

The QualityStocks Daily Newsletter would like to spotlight Save The World Air, Inc. (ZERO). Today, Save The World Air, Inc. closed trading at $0.47, off by 2.08%, on 62,150 volume with 23 trades. The stock’s average daily volume over the past 60 days is 126,825, and its 52-week low/high is $0.3401/$0.95.

Save The World Air, Inc. today announced its financial results for the fiscal year ended December 31, 2014, including net sales of $0.2 million. As a result of net sales realized and lower expense levels in fiscal 2014, STWA saw significant improvements in its bottom-line performance. In 2015, the company intends to continue the commercialization of its technologies, while working with industry and academia to further build out their global energy industry solutions.

Save The World Air, Inc. (ZERO) (“STWA”) provides the global energy industry with patent-protected industrial equipment designed to deliver measurable performance improvements to crude oil pipelines. Developed in partnership with leading crude oil production and transportation entities, STWA’s high-value solutions address the enormous capacity inadequacies of domestic and overseas pipeline infrastructures that were designed and constructed prior to the current worldwide surge in oil production.

In support of our clients’ commitment to the responsible sourcing of energy and environmental stewardship, STWA combines scientific research with inventive problem solving to provide energy efficiency ‘clean tech’ solutions to bring new efficiencies and lower operational costs to the upstream, midstream and gathering sectors. STWA’s flagship product, AOT (Applied Oil Technology) improves the economics of transporting crude oil by reducing the viscosity of oil in pipelines. Once deployed on pipeline pumping stations, production and transportation companies benefit from the safer, more cost-effective delivery of greater volumes of oil while reducing energy consumption at pumping stations and lowering CO2 emissions.

The AOT technology is the result of years of research conducted at Temple University (Philadelphia, Penn.) and is the world’s first ASME-certified industrial hardware to use the principles of electrorheology, the study of applying non-uniform electrical fields to change the mechanical behavior of fluids, to significantly reduce the viscosity of crude oil within pipelines during maximum flow conditions. Field tested by the U.S. Department of Energy, independent testing laboratories such as ATS RheoSystems and fabricated to exacting industry standards by STWA’s supply chain partners, the efficacy of AOT to increase flow rates, prevent bottlenecks, reduce pump station power consumption, enhance pipeline integrity and optimize flow assurance has been proven repeatedly in the lab and on a 300,000 barrel per day pipeline.

STWA is also commercializing STWA Joule Heat, an energy-efficient technology for heating crude oil in pipelines to improve flow. Unlike traditional trace heating systems which generate heat via a resistive trace heating element which transfers energy into the oil, the STWA solution applies an electrical field directly to oil, generating heat within the flow itself. The result is optimal heat conductivity and performance with less power and in a smaller form factor.

Guided by a dynamic management team led by Greggory Bigger, Chief Executive Officer, Chairman and a strong independent board of directors of energy industry veterans, STWA is a revenue generating company with a solid cash position, clean balance sheet and a proven ability to develop and deliver industrial-grade equipment that support the company’s mission and enhance shareholder value. As the exclusive licensee of oil viscosity reduction processes developed at Temple University and owner of 48 worldwide patents related to the use of electricity to change the mechanical behavior of oil and liquid natural gas, STWA is well-positioned to capitalize on the explosive growth opportunities in the global crude oil production and transportation sector. More information is available at: www.stwa.com. Disclaimer

Save The World Air, Inc. Company Blog

Save The World Air, Inc. News:

STWA Reports 2014 Year-End Financial Results and Provides Operational Update

STWA Sets Date for Its Year-End 2014 Earnings Results Release and Conference Call

STWA Deploys AOT(TM) Viscosity Reduction System on Condensate Pipeline in Eagle Ford

One World Holdings, Inc. (OWOO)

The QualityStocks Daily Newsletter would like to spotlight One World Holdings, Inc. (OWOO). Today, One World Holdings, Inc. closed trading at $0.0055, up 27.91%, on 4,653,282 volume with 90 trades. The stock’s average daily volume over the past 60 days is 3,470,650, and its 52-week low/high is $0.0008/$0.2499.

One World Holdings, Inc. (OWOO) subsidiary, The One World Doll Project, was established in 2010 to make a significant positive cultural impact through the doll category, transcending global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.

In 2013, the company released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations. For young girls, the dolls are a friend, a partner in play, and a glimpse of their biggest, brightest dreams. For young women, the dolls are a symbol of who they are and what they can achieve. For doll connoisseurs, The One World Doll Project promises stylish works of art that will become a vital part of a growing collectors’ market.

The One World Doll Project also has a Signature Celebrity Collection of Prettie Girls! and in 2013 released its first celebrity collectors doll modeled after supermodel Cynthia Bailey from The Real Housewives of Atlanta. Since the release of the doll, it has been showcased with Synthia on The Arsenio Hall Show, What Happens Live with Andy Cohen and The Bethenny Show.

Using a web-based sales model, One World Holdings plans to quickly capture significant market share in the dolls and stuffed toys space. After securing a strong online presence, the company will focus on brick and mortar retailing as it moves toward the ultimate pursuit of expanding worldwide. The company has established distribution deals with Toys “R” Us, HEB, dollgenie.com, Tuckers Toy Shop, pattycakedoll.com, and has recently expanded its retail presence internationally with the People’s Pharmacy storechain in the Central American country of Belize. The Prettie Girls! Dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine, Bloomberg.com, Parade.com, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and TheStreet.com. Disclaimer

One World Holdings, Inc. Company Blog

One World Holdings, Inc. News:

The One World Doll Project CEO Announces 2015 Revenue Projections in Stockholder Letter

The One World Doll Project and Doll Designer, Stacey Mcbride-Irby Featured in Huffington Post

The One World Doll Project Founder Interviews With CEOLIVE.TV; Updates on Toy Fair 2015

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.15, up 7.14%, on 28,100 volume with 11 trades. The stock’s average daily volume over the past 60 days is 33,902, and its 52-week low/high is $0.13/$1.00.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial

Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible

Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device

Falcon Crest Energy (FCEN)

The QualityStocks Daily Newsletter would like to spotlight Falcon Crest Energy (FCEN). Today, Falcon Crest Energy closed trading at $0.01591, up 0.06%, on 2,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 8,186, and its 52-week low/high is $0.0066/$0.095.

Falcon Crest Energy (FCEN) is a development stage oil and gas exploration and production company focused on developing properties in North America. The company plans to minimize the risk of exploration through development of proved petroleum reserves, and expects to maximize profit through strategic acquisition and liquidation of selected oil and gas properties.

The company specializes in acquiring low risk, high upside properties with substantial exploration potential. Through improvements in oil and gas production technologies, Falcon Crest Energy aims to rapidly increase production levels and generate predictable, sustainable value. The business strategy utilized calls for both 100% acquisitions and joint-ventures to maximize production capacity.

Evergreen Petroleum, a joint venture partner, is working closely with the company to explore oil-bearing formations in Wyoming. Evergreen has conducted and will continue to conduct both regional and local geological studies to define prospects that are worthy of acquiring oil and gas leases. By partnering with industry experts such as Evergreen, Falcon Crest Energy has strategically added extensive technical guidance and field management experience.

Even during challenging times, the world depends on oil & gas exploration and production companies to deliver millions of barrels of oil every day. Increased demand from emerging countries such as China further escalates competition for this precious resource. Backed by an experienced group of professionals, Falcon Crest Energy is well positioned to generate substantial revenues in the short and long term future. Disclaimer

Falcon Crest Energy Company Blog

Falcon Crest Energy News:

Falcon Crest Energy Acquires Remaining Working Interest in Rocky Ford Field

Falcon Crest Names Michael Cvetanovic to Advisory Council

Falcon Crest Energy Announces Powder River Basin Leasehold Acquisition

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $12.00, even for the day, on 29 volume with 1 trade. The stock’s average daily volume over the past 60 days is 629, and its 52-week low/high is $3.16/$15.00.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board

VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder

Cleartronic, Inc. (CLRI)

The QualityStocks Daily Newsletter would like to spotlight Cleartronic, Inc. (CLRI). Today, Cleartronic, Inc. closed trading at $0.09, even for the day, on 900 volume with 1 trade. The stock’s average daily volume over the past 60 days is 819, and its 52-week low/high is $0.04/$0.5499.

Cleartronic, Inc. (CLRI) is a technology holding company that creates and acquires operating subsidiaries to develop, manufacture and sell products, services and integrated systems to government agencies and business enterprises.

VoiceInterop, Inc., a wholly owned subsidiary, is a provider of patented IP communication gateways and communication software. Its gateways are marketed worldwide direct to customers as well as through a network of value added resellers. VoiceInterop has also developed an interoperable communication solution for use by airports. The company markets, installs and supports this interoperability solution directly to airports. International airports currently using the VoiceInterop communication solution include Dulles, Reagan, Omaha, Cincinnati, Green Bay and West Palm Beach.

A recent license agreement provides Cleartronic with the right to market Collabria LLC’s revolutionary ReadyOp™ command, control and communication platform. ReadyOp is a web-based application that integrates multiple databases and a robust communications platform supporting day-to-day activities for planning and managing small- and large-scale events. ReadyOp is designed for fast, efficient access to information and for communication with multiple persons, groups and agencies. ReadyOp is currently being used by numerous federal, state and local government agencies and private enterprises.

Backed by a management team committed to growing its business and finding ways to create value for shareholders, Cleartronic is well-positioned to grow in a broad array of markets. The company has a solid business plan in place that maximizes available resources for accelerated growth and has proven its ability to identify strong business opportunities. Disclaimer

Cleartronic, Inc. Company Blog

Cleartronic, Inc. News:

Cleartronic Announces Expanded License Agreement With Collabria LLC

Cleartronic Appoints Two New Members to Board of Directors

Cleartronic, Inc. (CLRI) Announces Capitalization Benefit Plan and Expansion of Board of Directors

Mobile Lads Corp. (MOBO)

The QualityStocks Daily Newsletter would like to spotlight Mobile Lads Corp. (MOBO). Today, Mobile Lads Corp. closed trading at $0.0951, even with yesterday's close. The stock’s average daily volume over the past 60 days is 51,196, and its 52-week low/high is $0.091/$0.42.

Mobile Lads Corp. (MOBO) designs and delivers secure, wide-area wireless transaction software solutions for the consumer finance, web and health payment processing sectors. The company’s solutions provide streamlined, continuous access to time-sensitive information and data on multiple network standards. Mobile Lads’ products and services, offered through its Xtreme Mobility division, centers on three core technologies that simplify and secure wireless communications: xmVerify, xmBilling, and xmOne.

xmVerify is a real-time mobile transaction security service that prevents credit card fraud by giving users control over the authorization process when making purchases. Using one of the best cryptographic services, and in compliance with most all available platforms, xmVerify sends a transaction authorization request directly to the user’s mobile phone to ensure authenticity.

xmBilling is a mobile platform that provides customers with a convenient and secure way to review and authorize automatic billing transactions, easing the challenges of automated and volume-based billing. The system sends the user a text message with a URL leading to an online e-bill where they can review details of the bill and authorize the payment via credit card with the use of their PIN number.

The xmOne mobile platform provides an array of encrypted mobile services, including top-up, payment processing, emergency notification and marketing, ideal for students and higher education facilities. xmOne interfaces with a school’s existing campus card account system to enable students to perform a variety of banking transactions from their cell phones. The university or college benefits from increased usage of the flex-dollar ecosystem, reduces overhead from ADMs, and can be customized to each school’s individual brand.

Mobile Lads is guided by a management team with a unique blend of in-depth technical expertise in wireless channel communications and a solid background in business strategy and consumer analysis. The company’s vision is to grow as a leading-edge wireless solution provider by enabling innovative, wide-area communication solutions on a global scale. Disclaimer

Mobile Lads Corp. Company Blog

Mobile Lads Corp. News:

Mobile Lads Purchases Majority of North American Shopping Network From Domark International

Mobile Lads to Launch CouBox, a Next-Generation Mobile Coupon Application

Mobile Lads Acquires Innovative Online Coupon Platform, CouBox


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters







Wall Street Resources

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251